Gilead Sciences (GILD) Tops Q1 EPS by 4c; maintains guidance

Gilead Sciences (NASDAQ: GILD) reported Q1 EPS of $1.81, $0.04 better than the analyst estimate of $1.77. Revenue for the quarter came in at $6.67 billion versus the consensus estimate of $6.78 billion.

GUIDANCE:

Gilead Sciences sees FY2025 EPS of $7.70-$8.10, versus the consensus of $7.95. Gilead Sciences sees FY2025 revenue of $28.2-28.6 billion, versus the consensus of $28.729 billion.

For earnings history and earnings-related data on Gilead Sciences (GILD) click here.

You May Also Be Interested In

• Kalshi in early talks for IPO - The Information
• JPMorgan Upgrades Sika AG (SIKA:SW) (SKFOF) to Neutral
• Alamos Gold Inc. (AGI:CN) (AGI) PT Lowered to Cdn$73 at BMO Capital